MedPath

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Phase 3
Terminated
Conditions
Melanoma
Interventions
Registration Number
NCT00522834
Lead Sponsor
Synta Pharmaceuticals Corp.
Brief Summary

"Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells. This response is characterized by increased production of gene families that protect against different cellular stresses, including excessive heat, the presence of reactive oxygen species such as oxygen radicals, or the presence of heavy metals.

Subjects will participate in up to 2 weeks of screening during which time they will complete all screening procedures. Eligible subjects who have not received any prior cytotoxic chemotherapeutic agent for melanoma will be randomized in a 1:1 ratio to receive either STA-4783 213 mg/m2 in combination with paclitaxel 80 mg/m2 or paclitaxel 80 mg/m2 alone.

One treatment cycle will consist of weekly treatments for 3 weeks, followed by a 1-week rest period. Cycles will be repeated every 4 weeks until disease progression. Tumor assessments will be performed every 8 weeks from the date of randomization or sooner if the Investigator suspects progression has occurred based on clinical signs and symptoms. "

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
630
Inclusion Criteria
  • Histologically confirmed metastatic (Stage IV) melanoma of cutaneous origin
  • ECOG performance status of <=2
  • Measurable disease according to modified RECIST
  • Life expectancy of greater than 12 weeks
  • LDH <= 2.0 x ULN
  • Clinical lab values within protocol parameters.
  • At least 18 years old and able and willing to provide informed consent to participate
Exclusion Criteria
  • Previous cytotoxic chemotherapy treatment for melanoma
  • Received more than one regimen of immunotherapy, kinase inhibitor, biologic therapy, vaccine or investigational non-chemotherapeutic treatment for melanoma.
  • Presence of brain metastases
  • Presence or history (<= 5 years) of a second malignancy other than nonmelanoma skin cancer or cervical carcinoma in situ
  • Female subjects who are pregnant or nursing

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1Elesclomol (STA-4783)Elesclomol (STA-4783) in Combination With Paclitaxel
2PaclitaxelPaclitaxel alone
Primary Outcome Measures
NameTimeMethod
Progression free survivalJune 2009
Secondary Outcome Measures
NameTimeMethod
Overall SurvivalDecember 2009
Clinical benefit rateDecember 2009
SafetyDecember 2009
PharmacokineticsDecember 2009
Objective response rateDecember 2009
Duration of objective responseDecember 2009

Trial Locations

Locations (99)

The Ohio State University.

🇺🇸

Columbus, Ohio, United States

Cancer Pavilion

🇺🇸

Pittsburgh, Pennsylvania, United States

University of California San Diego Moores UCSD Cancer Center

🇺🇸

La Jolla, California, United States

Goshen Center for Cancer Care

🇺🇸

Goshen, Indiana, United States

Monter Cancer Center North Shore Hospital

🇺🇸

Lake Success, New York, United States

Leo W. Jenkins Cancer Center

🇺🇸

Greenville, North Carolina, United States

Piedmont Hospital

🇺🇸

Atlanta, Georgia, United States

Jonsson Comprehensive Cancer Center Univ. of California Los Angeles

🇺🇸

Los Angeles, California, United States

Arizona Cancer Center

🇺🇸

Tucson, Arizona, United States

Redwood Regional Medical Group

🇺🇸

Santa Rosa, California, United States

Carolina Hematology & Oncology Associates

🇺🇸

Charlotte, North Carolina, United States

Ellis Fischels Cancer Center

🇺🇸

Columbia, Missouri, United States

Marshfield Clinic

🇺🇸

Marshfield, Wisconsin, United States

Princess Alexandra Hospital

🇦🇺

Wooloongabba, Queensland, Australia

Brody School of Medicine at East Carolina State University

🇺🇸

Greenville, North Carolina, United States

Fox Chase Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

Stony Brook University Medical Center- Cancer Center

🇺🇸

Stony Brook, New York, United States

Lismore Base Hospital, Cancer Care & Haematology Unit

🇦🇺

Lismore, New South Wales, Australia

Newcastle Melanoma Unit - Calvary Mater Newcastle

🇦🇺

Waratah, New South Wales, Australia

Hospital Universitario de la Princessa Servicio de Oncología Médica

🇪🇸

Madrid, Spain

Oncology- Chemotherapy Clinic - Emergency Municipal Clinical Hospital

🇷🇴

Timisoara, Romania

VA Medical Center

🇵🇷

San Juan, Puerto Rico

Northern Centre for Cancer Treatment Newcastle General Hospital

🇬🇧

Newcastle upon Tyne, United Kingdom

Dana Farber Cancer Institute

🇺🇸

Boston, Massachusetts, United States

Hubert H. Humphrey Cancer Center

🇺🇸

Robbinsdale, Minnesota, United States

University of California, San Diego

🇺🇸

La Jolla, California, United States

The Angeles Clinic & Research Institute

🇺🇸

Los Angeles, California, United States

Bay Pines VA Healthcare System

🇺🇸

Bay Pines, Florida, United States

Emory University Winship Cancer Institute

🇺🇸

Atlanta, Georgia, United States

Rush University Hospital

🇺🇸

Chicago, Illinois, United States

Oncology Specialists, S.C.

🇺🇸

Niles, Illinois, United States

Evanston Northwestern Healthcare

🇺🇸

Evanston, Illinois, United States

Joliet Oncology/Hematology Associates, LTD

🇺🇸

Joliet, Illinois, United States

Oncology Specialists, SC

🇺🇸

Park Ridge, Illinois, United States

Beth Israel Deaconess Medical Center

🇺🇸

Boston, Massachusetts, United States

Mark H. Zangmeister Cancer Center

🇺🇸

Columbus, Ohio, United States

Abramson Cancer Center at University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

St. Luke's Cancer Center

🇺🇸

Bethlehem, Pennsylvania, United States

Texas Oncology, PA

🇺🇸

Dallas, Texas, United States

Virginia Oncology Associates

🇺🇸

Norfolk, Virginia, United States

Seattle Cancer Care Alliance

🇺🇸

Seattle, Washington, United States

Southern Medical Day Care Centre

🇦🇺

Wollongong, New South Wales, Australia

Redcliffe Hospital

🇦🇺

Redcliffe, Queensland, Australia

Royal Adelaide Cancer Centre Medical Oncology

🇦🇺

Adelaide, Australia

Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital

🇦🇺

North Sydney, Australia

The Tweed Hospital

🇦🇺

Tweed Heads, Australia

Department of Medical Oncology, Westmead Hospital

🇦🇺

Westmead, Australia

Tom Baker Cancer Centre

🇨🇦

Calgary, Alberta, Canada

Northeastern Ontario Regional Cancer Centre

🇨🇦

Sudbury, Ontario, Canada

Univ. of Miami Hospital and Clinics

🇺🇸

Miami, Florida, United States

Indiana University Melvin and Bren Simon Cancer Center

🇺🇸

Indianapolis, Indiana, United States

Cross Cancer Institute

🇨🇦

Edmonton, Canada

Princess Margaret Hospital

🇨🇦

Toranto, Canada

Vivantes Klinikum Im Friedrichshain

🇩🇪

Berlin, Germany

Vivantes Klinikum Neukölln

🇩🇪

Berlin, Germany

Elbe-Klinikum Buxtehude

🇩🇪

Buxtehude, Germany

University Frankfurt

🇩🇪

Frankfurt/Main, Germany

University of Kiel

🇩🇪

Kiel, Germany

Universität zu Köln

🇩🇪

Köln, Germany

Universitätsklinikum Leipzig

🇩🇪

Leipzig, Germany

Universitätsklinikum Würzburg

🇩🇪

Würzburg, Germany

Universitätsklinikum Mannheim

🇩🇪

Mannheim, Germany

Universitätsklinikum Münster

🇩🇪

Münster, Germany

Oncology Institute "Prof. Dr. Ion Chiricuta"

🇷🇴

Cluj Napoca, Romania

Clinical County Hospital " Alexandru Simionescu" Hunedoara

🇷🇴

Hunedoara, Romania

Clinical County Hospital Sibiu

🇷🇴

Sibiu, Romania

Clinica Universitaria de Navarra

🇪🇸

Pamplona, Spain

Hospital Virgen de la Salud - Servicio de Oncología Médica Ciclos

🇪🇸

Toledo, Spain

Oncology Centre Addenbrookes's Hospital

🇬🇧

Cambridge, United Kingdom

The Christ Hospital

🇺🇸

Cincinnati, Ohio, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

San Antonio Cancer Institute

🇺🇸

San Antonio, Texas, United States

Fremantle Hospital

🇦🇺

Fremantle, Western Australia, Australia

Anschutz Cancer Pavillion University of Colorado

🇺🇸

Aurora, Colorado, United States

Atlantic Health Research - Mountainside Hospital

🇺🇸

Montclair, New Jersey, United States

Hospital Universitario Central de Asturias

🇪🇸

Oviedo, Asturias, Spain

QE II Health Sciences Center

🇨🇦

Halifax, Nova Scotia, Canada

Winthrop P. Rockefeller Cancer Institute

🇺🇸

Little Rock, Arkansas, United States

Royal Hobart Hospital

🇦🇺

Hobart, Tasmania, Australia

Southeast Nebraska Hematology/Oncology

🇺🇸

Lincoln, Nebraska, United States

Dartmouth Hitchcock Medical Center

🇺🇸

Lebanon, New Hampshire, United States

Cancer Center of the Carolinas

🇺🇸

Greenville, South Carolina, United States

Hematology Oncology, P.C.

🇺🇸

Stamford, Connecticut, United States

County Hospital Brasov - Oncology Department

🇷🇴

Brasov, Romania

Center of Medical Oncology

🇷🇴

Iasi, Romania

Mary Bird Perkins Cancer Center

🇺🇸

Baton Rouge, Louisiana, United States

Dorset Cancer Centre Poole Hospital NHS Foundation Trust

🇬🇧

Poole, United Kingdom

University of New Mexico Cancer Center

🇺🇸

Albuquerque, New Mexico, United States

Weill Medical College of Cornell University - Division of Hematology and Medical Oncology

🇺🇸

New York, New York, United States

NYU Clinical Cancer Center

🇺🇸

New York, New York, United States

Pacific Medical Center Research Institute

🇺🇸

San Francisco, California, United States

MD Anderson Cancer Center

🇺🇸

Orlando, Florida, United States

Karmanos Cancer Institute, Wayne State University

🇺🇸

Detroit, Michigan, United States

Nebraska Methodist Cancer Center

🇺🇸

Omaha, Nebraska, United States

UNC School of Medicine - Division of Hematology/Oncology

🇺🇸

Chapel Hill, North Carolina, United States

Derrick L. Davis Regional Cancer Center

🇺🇸

Winston-Salem, North Carolina, United States

Providence Cancer Center Clinical Trials

🇺🇸

Portland, Oregon, United States

Vanderbilt Medical Center

🇺🇸

Nashville, Tennessee, United States

Virginia Cancer Institute

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath